Mutations of the MED13L gene, which encodes a subunit of a transcriptional regulatory complex, result in a complex phenotype entailing physical and cognitive anomalies.
INTRODUCTION
Rare conditions involving language deficits and resulting from point mutations in the coding region of genes provide crucial evidence of how the linguistic brain is wired in response to genetic guidance. The MED13L gene encodes a subunit of the mediator complex (a scaffolding protein device that promotes the assembly of functional preinitiation complexes with RNA polymerase II and the general transcription factors) that seemingly helps regulate the transcription of targets of the Wnt, Notch, and Shh signalling pathways (Asadollahi et al. 2013 , Davis et al. 2013 , Utami et al. 2014 ).
Among other tissues, MED13L gene is highly expressed in the fetal and adult brain, particularly in the cerebellum after birth (Muncke et al. 2003 , Musante et al. 2004 ;
Human
Brain Transcriptome:
http://hbatlas.org/hbtd/images/wholeBrain/MED13L.pdf). MED13L alteration was initially reported to cause complex heart defects, but it is now clear that mutations of MED13L appear to underlie a gradient, also giving rise to facial dysmorphisms, intellectual disability, delayed speech and language, hypotonia, and/or behavioral difficulties (Adegbola et al. 2015 , Cafiero et al. 2015 . It has been hypothesized that these diverse effects may result from the involvement of the gene in neural crest induction (see Asadollahi et al. 2013 for discussion). As noted by Cafiero et al (2015) , MED13L haploinsufficiency, resulting from CNVs or from loss-of-function intragenic variants, causes a recognizable intellectual disability (ID) syndrome with distinctive facial features and with or without heart defects. Nevertheless, the clinical relevance of missense mutations in the MED13L gene is poorly understood, and only some cases have been described to present. This is particularly true regarding their effect on language and cognition.
In this paper, we report on a boy with a missense mutation affecting the N-terminal region of the MED13L protein, and provide a detailed characterization of his clinical features, with a focus on the linguistic and cognitive phenotype. We discuss our findings in the context of current studies of the genetic basis of language. and used for subsequent analyses.
METHODS

Linguistic, cognitive, and behavioral assessment
Fragile X syndrome determinants
CGG expansions affecting the gene FMR1 (the main determinant for X-fragile syndrome) were analyzed in the patient according to standard protocols. Polymerase chain reaction (PCR) of the fragile site was performed with specific primers and trinucleotide repeat size of the resulting fragments were evaluated.
Microrrays for CNVs search and chromosome aberrations analysis
Patient DNA was hybridized on a CGH platform (Cytochip Oligo ISCA 60K). The DLRS value was > 0.10. The platform included 60.000 probes. Data were analyzed 6 with Agilent Genomic Workbench 7.0 and the ADM-2 algorithm (threshold = 6.0;
aberrant regions had more than 5 consecutive probes).
Whole-exome sequencing (WES)
The panel used for the preparation of the library was designed by SureSelectXT Human All Exon V5 (Agilent Technologies). It captures > 35000 exons from > 19000 genes and the splicing flanking (5 bp) regions. The size is ~50Mb. Sequencing was performed with the HiSeq 2500 SystemTM (Illumina) sequencer. The reads obtained were filtered, based on quality parameters, and aligned to the reference genome (build 37 of genome Hg19), using the BWA alignment program (version 0.7.12). Sequence variations with respect to reference genome were detected using the GATK algorithm (version 2.3-9).
Variants were annotated with the latest available version of ION Reporter (Life Technologies) and an in-house developed pipeline, aimed to register the patient's variants according to a genetic type classification. Our analysis focused on variants found in coding or splicing regions. Changes included missense, nonsense and stoploss mutations, as well as nucleotide insertions or deletions, found in > 40% of the sequences obtained.
Sanger sequencing
For analysing in the patient's parents the variants of unknown significance identified by the WES study of the proband, a PCR was performed using specific primers for exons 2 and 37 of MED13L and ANK3 genes, respectively, according to the reference sequences NM_15335 and NM020987. Double-sense sequencing of PCR products was done in an automatic sequencer ABI 3130 DNA Analyzer (Applied Biosystems, Foster City, California, USA), with further study of sequence variants using software seqScape v2.5 (Life Technologies, CA).
RESULTS
Clinical History
The proband is a boy born after 38 weeks of normal gestation by eutocic deliver to a healthy 37 years old female. The most relevant clinical data at birth are summarized in Apgar score (1') 9
Apgar score (5') 10
Clinical diagnosis at birth Two achromatic spots in the body side. Neonatal sepsis from the first day of life (bilirubin levels of 3.1 mg/dl at 4 th day). Bilateral cryptorchidism. Developmental anomalies were soon reported by the parents, including lack of crying, absence of feeding demands, sucking weakness, reduced eye contact, hypotonia, and neck rigidity. Still, the baby seemed to enjoy physical contact and smiled regularly.
Motor development was also delayed. Generalized hypotonia was confirmed at 6 months. At age 2;0 mild axial hypotonia was still observed, whereas at age 4;10 some hypertonic symptoms were found by the neuropediatrician. Self-hurting behavior was reported at age 4;10. The boy only started to walk without aid at age 3;0. Stereotypic movements were reported from age 3;0. Dysmorphic features included reduced palpebral fissures, nasal base enlargement, enlarged plane philtrum, a thinner upper lip, low-set ears, and a prominent columella. Hypermetropia was diagnosed at age 4;10.
The boy started attending a normal nursery school at age 1;4, but a month later was transferred to an early care center for disabled children, where he was reported to interact with his peers normally. At present (age 5;4) he is attending a normal school.
Self-hurting behavior is still present. Sphincter control has not been yet achieved.
Feeding problems are still observed, to the extent that he is only able to eat grinded food.
Language and cognitive development
Early language milestones were achieved late by the child. Cooing was first observed at six months, whereas reduplicated babbling was observed at age 1;6 only. Learning of a first word (agua 'water') was reported at age 1;0, but it was lost soon and no further progress was observed in his expressive abilities. At age 2;0 the boy didn't attend others upon request and was unable to understand simple commands.
From age 1;5 onwards the child started to received speech therapy 4 times a week.
Comprehension improved and at present, he is able to understand forbidding utterances ('Don't do this', 'Don't touch that') and usually reacts to simple direct commands In the ComFor test, which evaluates precursors of communication ability, he performed correctly series 1 to 3 from Level I, but failed with Level II tasks., suggesting that his representation abilities are severely affected.
Molecular and cytogenetic analysis
Routine molecular and cytogenetic analyses of the boy were performed at ages 2;7-2;8. Mutations of clinical interest are shadowed in medium and dark grey. 
Discussion
The development of next generation sequencing facilities has allowed identify many new genes and many new variants of known genes related to clinical conditions entailing problems with language. In this paper, we have characterized the linguistic and cognitive profile of a boy with a novel heterozygous missense mutation in the MED13L gene, which is predicted to affect to the N-terminal domain of the protein.
Our proband exhibits most of the cognitive and behavioral features of the MED13L haploinsufficiency syndrome, without congenital heart defect, and particularly, all the abnormal features linked to missense mutations in the gene ( MED13L is a candidate for ASD (Iossifov et al. 2012 ) and this could explain the ASD features of the proband, which includes language delay, no deictical pointing, absence of symbolic behavior, and stereotyped behavior. Additionally, MED13L is functionally related to several candidates for language and cognitive disorders, specifically with EP300 and CREBBP (Krebs et al. 2010 , Galbraith et al. 2013 . Interestingly, the proteins encoded by these two genes serve as link between the FOXP2 and ROBO1 networks, which play a central role in the regulation of brain areas involved in speech and language processing (see Boeckx and Benítez-Burraco 2014 for details). Also, mutations in both EP300 and CREBBP are candidates for different subtypes of Rubinstein-Taybi syndrome (OMIM#613684 and OMIM#180849, respectively), a clinical condition entailing mental and growth retardation, skeletal abnormalities, and brain abnormalities mostly impacting in the rolandic area, which is crucial for language processing (Sener, 1995 , Viosca et al. 2010 . Interestingly too, Crebbp(+/-) mice exhibit altered vocal behavior (Wang et al. 2010 ) and the knock-out of the gene in postmitotic neurons of the forebrain results in problems for object recognition (Valor et al. 2011 ).
Regarding to the EP300 gene, mutations in the gene usually give rise to less severe mental impairment, more severe microcephaly, and more changes in facial bone structure (Hennekam, 2006) . Finally, we wish highlight the role played by MED13L in neural crest induction. Interestingly, neurocristopathies (that is, conditions resulting from neural crest defects) usually entail skull, cognitive, and language features (see Benítez-Burraco et al. 2016 for discussion), but may also involve autistic features too, as observed in CHARGE syndrome (OMIM#214800) (Fernell et al. 1999) . It is also worth highlighting the involvement of MED13L in the Shh pathway, which plays a key role in neural crest cell proliferation and fate (Wada et al. 2005 , Calloni et al. 2007 , Delloye-Bourgeois et al. 2014 . The Shh pathway also regulates axonal growth and synaptogenesis in different parts of the brain (Bourikas et al. 2005; Salie et al. 2005 ).
An excess of SHH activity results in facial dysmorphisms, mental retardation, and lack of language acquisition (Guion-Almeida and Richieri-Costa, 2009). Lastly, Shh also regulates the topographical sorting of thalamocortical axons and motor neurons important for speech (see Boeckx and Benítez-Burraco, 2014 for details).
CONCLUSIONS
Although the exact molecular causes of the language and cognitive impairment exhibited by our proband remain to be elucidated, we expect that they result from the change we have uncovered in a conserved residue of the N-terminal domain of the MED13L protein. At the best of our knowledge, the missense mutation found in our proband is the second missense mutation in MED13L explicitly linked to language problems. In our case, we have provided with an exhaustive characterization of the language impairment observed in the child bearing this novel mutation. We have hypothesized that this mutation might have altered the functionality of the protein and/or its translocation to the nucleus, thus reducing the available amount of functional MED13L and impacting on the functions performed by the protein during embryonic development and after birth as part of the mediator complex. We expect that this clinical case helps improve our knowledge of the clinical presentation of missense variants within this important gene and ultimately, for our understanding of the genetic foundations of the human faculty for language.
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